

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/758,126	01/12/2001	Kazuhiro Tsujita	Q61243	8903	
7590 05/19/2006 SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC 2100 Pennsylvania Avenue, N.W., Washington, DC 20037-3202			EXAMINER		
			MANTIS MERCADER, ELENI M		
			ART UNIT	PAPER NUMBER	
washington, DC 20037-3202			3768		
				DATE MAILED: 05/19/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/758,126	TSUJITA ET AL.
Office Action Summary	Examiner	Art Unit
	Eleni Mantis Mercader	3768
The MAILING DATE of this communication ap	ppears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPI WHICHEVER IS LONGER, FROM THE MAILING I - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the maili earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tind will apply and will expire SIX (6) MONTHS from te, cause the application to become ABANDONE	I. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on 15 I This action is FINAL . 2b) ☑ This 3) ☐ Since this application is in condition for allowed closed in accordance with the practice under	is action is non-final. ance except for formal matters, pro	
Disposition of Claims		
4) Claim(s) 1-15 and 33-43 is/are pending in the 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) 1-15 and 33-43 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/ Application Papers 9) The specification is objected to by the Examin	awn from consideration. For election requirement.	
10) The drawing(s) filed on is/are: a) accomposition and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct should be shown as a composition of the should be should be should be shown as a composition of the should be	cepted or b) objected to by the less of th	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
 12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document * See the attached detailed Office action for a list 	nts have been received. Its have been received in Applicationity documents have been received au (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Profesorous's Potent Province Review (PTO 048)	4) Interview Summary	
 Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date 	Paper No(s)/Mail Da 3) S) Notice of Informal P 6) Other:	atent Application (PTO-152)

Application/Control Number: 09/758,126 Page 2

Art Unit: 3768

DETAILED ACTION

Response to Arguments

1. Applicant's arguments filed on 3/15/2006 have been fully considered but they are not persuasive. Applicant should note that the rejection is not under a 102 but rather under a 103. The Examiner explained that while there is no explicit mention of thresholds or values, still the Palcic et al.'190 reference teaches the use of a remittance image to account for non-uniformity due to different changes including illumination intensity (see col. 2, lines 28-31). The prosecution of the case is re-opened in order to address the newly added claims 39-43.

Claim Objections

2. Claims 39-43 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. The claims merely recite the response of the tissue to excitation light, which is a natural process rather than how the invention utilizes that response to provide a useful result. As such these responses do not further limit.

Claim Rejections - 35 USC § 101

- 3. 35 U.S.C. 101 reads as follows:
 - Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
- 4. Claims 39-43 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. These claims recite the natural response of a tissue to excitation light. As such they do not fall under the statutory categories of invention.

Application/Control Number: 09/758,126 Page 3

Art Unit: 3768

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 6. Claims 1-15 and 33-43 are rejected under 35 U.S.C. 103(a) as being unpatentable over Palcic et al.'190 (US Patent 5,827,190).

Palcic et al.'190 teach normalization of at least one fluorescence image by using a remittance image or as otherwise stated, reflected reference light image, in order to correct for many factors including light intensity allowing for differentiation of normal and diseased tissue (see col. 2, line 20-col. 3, line 37). Palcic et al.'190 teaches the use of a remittance image to account for non-uniformity due to different changes including illumination intensity (see col. 2, lines 28-31).

While Palcic et al.'190 do not specifically address specified values, it would have been obvious to one skilled in the art at the time that the invention was made that the normalization process necessarily incorporates specified values or thresholds in order to differentiate normal from abnormal tissue as this is well within the knowledge of skilled artisans.

With respect to the newly added claims, necessarily the detected values of fluorescence will be above or below the remittance value depending on whether the tissue is normal or abnormal.

Art Unit: 3768

7. Any inquiry concerning this communication should be directed to Eleni Mantis Mercader at telephone number (571) 272-4740.

Eleni Mantis Mercader

SPE

Art Unit 3768